Concentration of soluble adhesion molecules (sVCAM-1, sICAM-1 and sL-Selectin) in the cerebrospinal fluid and serum of patients with multiple sclerosis and systemic lupus erythematosus with central nervous involvement

被引:41
作者
Baraczka, K
Nékám, K
Pozsonyi, T
Jakab, L
Szongoth, M
Seszták, M
机构
[1] Natl Inst Rheumatism & Physiotherapy, Dept Neuroimmunol, H-1525 Budapest 114, Hungary
[2] Semmelweis Univ, Dept Internal Med 3, Budapest, Hungary
关键词
sICAM-1; sVCAM-1; sL-selectin; multiple sclerosis; systemic lupus erythematosus; cerebrospinal fluid;
D O I
10.1159/000049007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The aim of the present study was to investigate the role of soluble adhesion molecules in the pathogenesis of multiple sclerosis (MS) and systemic lupus erythematosus (SLE) with demyelinating syndrome. Methods: Paired cerebrospinal fluid (CSF) and serum samples were analysed by an ELISA method to determine the concentrations of sVCAM-1, sICAM-1 and sL-selectin. Intrathecal syntheses of the adhesion molecules were calculated. Results: Elevated serum and CSF concentrations of sVCAM-1 were present in all patient groups. Intrathecal synthesis of sVCAM-1 was present in the relapsing-remitting and secondary progressive forms of MS. Intrathecal synthesis of sICAM-1 was observed in all clinical forms of MS. MS patients with progressive forms of the disease and SLE patients were characterised by intrathecal synthesis of sL-selectin. Conclusions: The data presented suggest that (1) blood-brain barrier damage can be assumed both in systemic disease and organ-specific disease (sVCAM-1), (2) clinical forms of MS differ from each other in respect to concentrations of adhesion molecules and (3) similar immunological events in the central nervous system of SLE patients with demyelinating syndrome and progressive forms of MS can be assumed (sL-selectin). Copyright (C) 2001 S. Karger AG, Basel.
引用
收藏
页码:49 / 54
页数:6
相关论文
共 38 条
[1]   Soluble L-selectin levels in serum and cerebrospinal fluid in patients with multiple sclerosis and systemic lupus erythematosus [J].
Baraczka, K ;
Pozsonyi, T ;
Nékám, K ;
Virányi, M ;
Seszták, M ;
Szongoth, M ;
Jakab, L .
ACTA NEUROLOGICA SCANDINAVICA, 2000, 102 (02) :114-117
[2]  
BARACZKA K, 1998, ACTA NEUROL SCAND, V98, P1
[3]   UP-REGULATION OF ENDOTHELIAL-CELL ADHESION MOLECULES CHARACTERIZES DISEASE-ACTIVITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS - THE SHWARTZMAN PHENOMENON REVISITED [J].
BELMONT, HM ;
BUYON, J ;
GIORNO, R ;
ABRAMSON, S .
ARTHRITIS AND RHEUMATISM, 1994, 37 (03) :376-383
[4]   Serum thrombomodulin - a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity [J].
Boehme, MWJ ;
Raeth, U ;
Galle, PR ;
Stremmel, W ;
Scherbaum, WA .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2000, 119 (01) :189-195
[5]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[6]   CIRCULATING, SOLUBLE ADHESION PROTEINS IN CEREBROSPINAL-FLUID AND SERUM OF PATIENTS WITH MULTIPLE-SCLEROSIS - CORRELATION WITH CLINICAL ACTIVITY [J].
DOREDUFFY, P ;
NEWMAN, W ;
BALABANOV, R ;
LISAK, RP ;
MAINOLFI, E ;
ROTHLEIN, R ;
PETERSON, M .
ANNALS OF NEUROLOGY, 1995, 37 (01) :55-62
[7]   Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: Predominant intrathecal release of vascular cell adhesion molecule-1 [J].
Droogan, AG ;
McMillan, SA ;
Douglas, JP ;
Hawkins, SA .
JOURNAL OF NEUROIMMUNOLOGY, 1996, 64 (02) :185-191
[8]   Immunological profile of patients with primary progressive multiple sclerosis -: Expression of adhesion molecules [J].
Durán, I ;
Martínez-Cáceres, EM ;
Río, J ;
Barberá, N ;
Marzo, ME ;
Montalban, X .
BRAIN, 1999, 122 :2297-2307
[9]   ENHANCED ENDOTHELIAL-CELL ADHESION OF HUMAN CEREBROSPINAL-FLUID LYMPHOCYTES [J].
ELFONT, RM ;
GRIFFIN, DE ;
GOLDSTEIN, GW .
ANNALS OF NEUROLOGY, 1995, 38 (03) :405-413
[10]   Increased serum levels of soluble L-selectin (CD62L) in patients with active systemic lupus erythematosus (SLE) [J].
Font, J ;
Pizcueta, P ;
Ramos-Casals, M ;
Cervera, R ;
García-Carrasco, M ;
Navarro, M ;
Ingelmo, M ;
Engel, P .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2000, 119 (01) :169-174